Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Checked against the public recordLast updated Jan 17, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Expanded Access
- Phase
- Not applicable
- Sponsor
- Eli Lilly and Company
- Interventions being studied
- Drug: Selpercatinib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib * Have progressed or are intolerant to standard therapy, or no standard therapy option exists, or in the opinion of the investigator, are unlikely to derive significant clinical benefit from standard therapy * Have adequate organ function Exclusion Criteria: * Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor * Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to study treatment; ongoing cardiomyopathy; or current prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) interval greater than 470 milliseconds
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Cancer Treatment Centers of AmericaGoodyear, Arizona
- Mayo Clinic of ScottsdaleScottsdale, Arizona
- City of Hope National Medical CenterDuarte, California
- UCLA Medical CenterLos Angeles, California
- Kaiser PermanenteOakland, California
- Irvine Medical CenterOrange, California
- University of California - San DiegoSan Diego, California
- Univ of California San FranciscoSan Francisco, California
- Kaiser PermanenteSanta Clara, California
- Kaiser Permanente Medical CenterVallejo, California
- Memorial Cancer InstituteHollywood, Florida
- Mayo Clinic in FloridaJacksonville, Florida
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 17, 2025. Always confirm current availability with the study team.